Aim: JG6 is a novel marine-derived oligosaccharide that has shown to inhibit angiogenesis and tumor metastasis. In this study, we sought to identify the potential target responsible for the anti-cancer activity of JG6. Methods: Human liver cancer cell line Bel-7402 and human cervical cancer cell line HeLa were examined. CXCL12-stimulated cell proliferation and migration were determined using a CCK-8 kit and a transwell assay, respectively. Western blotting was performed to examine the changes in CXCL12/CXCR4 axis. Molecular docking and surface plasmon resonance (SPR) were performed to characterize the possible interaction between JG6 and the CXCL12/CXCR4 axis. Results: Treatment with CXCL12 potently stimulated the proliferation and migration in both Bel-7402 and HeLa cells. Co-treatment of the cells with JG6 (10, 50 and 100 μg/mL) dose-dependently impeded the CXCL12-stimulated cell proliferation and migration. Furthermore, CXCL12 rapidly induced phosphorylation of AKT, ERK, FAK and Paxillin in Bel-7402 and HeLa cells, whereas pretreatment with JG6 dose-dependently inhibited the CXCL12-induced phosphorylation of these proteins. The SPR assay showed that JG6 bound to CXCL12 with a high affinity. In molecular docking study, JG6 appeared to interact with CXCL12 via multiple polar interactions, including 6 ionic bonds and 7 hydrogen bonds. Conclusion: Inhibition of the CXCL12/CXCR4 axis by JG6 may account for its anticancer activity.
Introduction
CXCL12, also called stromal cell-derived factor-1 (SDF-1), is a CXC chemokine that binds primarily to CXC receptor 4 (CXCR4). This binding induces intracellular signaling that plays a pivotal role in chemotaxis, cell survival, proliferation, and metastasis of CXCR4+ tumor cells to organs that express CXCL12 [1, 2] . It has been reported that CXCR4+ cancers metastasize to bones and lymph nodes in a CXCL12-dependent manner [3, 4] . Therefore, the CXCL12/CXCR4 axis has emerged as a potential target for cancer therapy.
Increasing effort has been made in impeding the function of the CXCL12/CXCR4 axis by targeting either the ligand or the receptor using small-molecule receptor antagonists, receptorbinding antibodies, or modified chemokines [5, 6] . Among these options, blocking the access of CXCL12 to CXCR4 is an effective approach. It has been reported that glycosaminoglycans (GAGs) and syndecan-4 hindered the invasion of human tumor cells (HeLa cells) via blocking the interaction between CXCL12 and CXCR4 [7] , and this finding was supported by the structural analysis of CXCL12's interactions with GAGs [8, 9] .
Accordingly, heparin, a sulfated glycosaminoglycan, blocked CXCL12-induced human cancer cell growth, migration, and invasion [7, 10] . Furthermore, treatment of human hepatoma cells with a series of GAG mimetics inhibited CXCL12-induced migration and invasion [11] .
JG6 is a novel marine-derived oligosaccharide discovered in our laboratory. JG6 significantly suppressed cancer growth and metastasis in vitro and in vivo [12, 13] , but the mechanisms remain unclear. Importantly, we have noted that the structure of JG6 resembles the structure of GAGs. Here, we explored whether JG6 has potential anti-cancer activity through its intervention in the CXCL12/CXCR4 axis.
Reagents
JG6 was created by semi-synthesis followed by sulfate modification by reacting oligomannurarate from sodium alginate with ClSO 3 H in formamide. The pH of the products was adjusted to 7.0 with 4 mol/L NaOH and desalted using Sephadex G-10. The products were pooled and freeze-dried. Analysis was performed using High Performance Gel Permeation Chromatography (HPGPC) with a G3000W×1 column (300 mm×7.8 mm) (TOSOH, Japan). The structure is depicted in Figure 1 . JG6 is composed of β-(1-4) glycosidic linked D-mannurarate with sulfate modification of the hydroxyl group at the C2/C3 position. CXCL12 was purchased from R&D Systems (Minneapolis, MN, USA).
Cell culture
Bel-7402 human liver cancer cells and HeLa human cervical cancer cells were obtained from the Institute of Biochemistry and Cell Biology and the American Type Culture Collection, respectively. The cells were grown in RPMI-1640 or highglucose DMEM medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, USA) and antibiotics (100 U/mL penicillin and 100 μg/mL streptomycin). The cells were maintained in a 5% CO 2 humidified atmosphere at 37 °C.
Proliferation assay
Bel-7402 and HeLa cells were incubated in serum-free medium for 6 h and then exposed to various concentrations of JG6 (0, 10, 50, or 100 μg/mL) and CXCL12 (300 ng/mL) for 72 h. Cell proliferation was determined using a CCK-8 kit (Dojindo, Kumamoto, Japan).
Migration assay
The cell migration assay was performed in a transwell Boyden Chamber (8 μm pore size, Costar, MA, USA). Briefly, tumor cells (3.5×10 5 cells per well) were seeded in the top chamber of the transwell, whereas the lower chamber was filled with culture medium supplemented with 50 or 300 ng/mL CXCL12 plus JG6 (0, 10, 50, or 100 μg/mL). CXCL12 was not added to the negative control group. Cells were cultured for 24-36 h at 37 °C in a well-humidified incubator, and then the total migrated cells were fixed, stained with 0.1% crystal violet, and imaged under a microscope. Stained cells were extracted with 10% acetic acid and the OD value was measured at 595 nm.
Western blotting analysis
Cells were starved for 24 h, pre-incubated with JG6 (0, 10, 50, or 100 μg/mL) for 6 h, and then induced with CXCL12 (R&D, Minneapolis, MN, USA) at 50 ng/mL for 15 min. After incubation, cells were lysed in 1× SDS lysis buffer (50 mmol/L Tris-HCl pH 6.8, 100 mmol/L DTT, 2% SDS, 0.1% bromophenol blue, and 10% glycerol), and then the lysates were clarified by centrifugation at 14 000×g for 10 min. Equal amounts of protein were subjected to SDS-PAGE and transferred to nitrocellulose membranes (Amersham Pharmacia Biotech, USA). The membranes were blocked with 5% nonfat milk and incubated with the corresponding primary antibodies at 4 °C overnight. The immunoreactive bands were visualized by the SuperSignal West PicoChemiluminescent kit (Pierce Biotechnology, Rockford, IL, USA) using Image Quant LAS4000 (GE, USA). Primary antibodies used include antibodies specific for Phospho-Paxillin (Y118), Paxillin, Fak, phospho-Erk1/2, Erk1/2, phospho-Akt (Ser473) and Akt (Cell Signaling Technology, USA), p-Fak (pY861) (Invitrogen, USA), CXCL12 and CXCR4 (Abcam, UK).
Molecular docking
The NMR structure of chemokine CXCL12 was retrieved from the Brookhaven Protein Data Bank (PDB entry: 2K03). Chain A and chain C from 2K03 were retained as the receptor, whereas chain B was selected to define the grid box center. Molecular docking was performed using Glide with the XP mode [14, 15] . The compounds were sketched by Maestro and then processed by LigPrep with Epik to treat the protonation states. The docked conformations in the ligand-binding site were selected for further analysis.
Surface plasmon resonance analysis
The kinetics and specificity of the binding reaction between JG6 and CXCL12 were analyzed using the BIAcore surface plasmon resonance apparatus. Briefly, JG6 was immobilized on an NLC sensor chip according to the Ligand Thiol protocol described in BIA application handbook. To assess real-time binding capacity, 5-80 nmol/L of CXCL12 was injected over the sensor chip surface with the immobilized JG6 and then washed with HBS-EP buffer for 5 min. The sensor chip surface was regenerated using 60 μL of NaCl (2 mol/L). All binding experiments were performed at 25 °C with a constant flow rate of 10 μL/min of HBS-EP. For binding affinity assessment, the association phase was allowed to proceed to equilibrium.
The untreated surface moieties were blocked with ethanolamine. To correct for nonspecific binding and bulk refractive index changes, a blank channel (FC2) without oligosaccharide was employed as a control for each experiment. Sensorgrams for all binding interactions were recorded in real time, and the blank channel readings were subtracted from the results before analysis. Changes in mass due to the binding response were recorded as resonance units (Ru). Binding kinetics and affinities were determined by SPR using BIAcore software 3.1. 
Results

JG6 impeded CXCL12-induced cancer cell proliferation
The CXCL12/CXCR4 biological axis plays an important role in regulating tumor cell proliferation. First, we investigated whether JG6 had an impact on CXCL12-stimulated cell growth. The CCK-8 assay was applied to measure the cell proliferation rates of Bel-7402 cells and HeLa cells. CXCL12 stimulated tumor cell growth, as previously reported [10] . The proliferation rate was increased by almost 50% upon treatment with 300 ng/mL CXCL12 (Figure 2A ). This effect was largely reversed when cells were simultaneously treated with JG6. JG6 caused a dose-dependent suppression of CXCL12-stimulated Bel-7402 cell proliferation. The cell proliferation rate was inhibited by 22.2% at 10 µg/mL, 46.5% at 50 µg/mL, and 51.0% at 100 µg/mL. Similar results were observed in HeLa cells, for which treatment with 10, 50, or 100 µg/mL JG6 yielded 22.2%, 37.2%, and 41.5% lower cell proliferation rates, respectively, than in the absence of JG6 (Figure 2A ). However, JG6 did not inhibit Bel-7402 and HeLa cell proliferation in vitro in normal cell culture conditions (data not shown).
JG6 suppressed CXCL12-induced cancer cell migration
The CXCL12/CXCR4 biological axis is also known to modulate the chemotactic motility of cancer cells. We next evaluated whether JG6 had an inhibitory effect on this process. As shown in Figure 2B , Bel-7402 cells were responsive to CXCL12 induction at a JG6 concentration of 50 ng/mL for 48 h when a notable increase in migrating cells was observed compared to the negative control group (which was incubated without CXC12 and FBS). JG6 inhibited CXCL12-induced migration of Bel-7402 cells in a dose-dependent manner, yielding 100% inhibition at 100 µg/mL. Likewise, although HeLa cells were less responsive to CXCL12-stimulation than Bel-7402 cells, JG6 similarly reduced CXCL12-induced migration in HeLa cells by 44%, 88%, and 97% after treatment with 10, 50, or 100 µg/mL of JG6 ( Figure 2C ). However, JG6 did not impede Bel-7402 cell migration induced by 10% FBS (data not shown).
JG6 blocked CXCL12-induced signal transduction
We showed that JG6 effectively inhibited CXCL12-induced cell proliferation and migration in Bel-7402 and HeLa cells. We then proceeded to explore its effect on downstream signals of the CXCL12/CXCR4 axis. The Western blotting data presented in Figure 3 show that 50 ng/mL CXCL12 rapidly induced phosphorylation of AKT, ERK, FAK and Paxillin in Bel-7402 and HeLa cells, within 15 min. In contrast, pre-incubation with JG6 for 6 h inhibited CXCL12-induced phosphorylation of these proteins in a dose-dependent manner. Similar results were observed in HeLa cells.
JG6 interacted with CXCL12
We next assessed how JG6 affects CXCL12/CXCR4 axis signaling. Previous studies in our laboratory have suggested that the structure of JG6 resembles the structure of GAGs and that GAGs appear to interact with CXCL12. We therefore utilized the SPR assay to identify the possible interaction between CXCL12 and JG6. JG6 was immobilized on NLC sensor chips. When CXCL12 was injected into the biosensor, a typical increase in SPR response corresponding to the association phase was observed in a dose-dependent manner (5-80 nmol/L). Upon displacement of the chemokine by the running buffer, a remarkable decrease in the SPR response signal emerged, consistent with the dissociation phase ( Figure  4) . The binding curve was fitted and demonstrated a multivalent binding mode with a clear association rate constant (k on ) of 11.7 nmol/L and an equilibrium dissociation rate constant of 16.5 nmol/L. These data supported the findings above that indicate JG6 has a high affinity for CXCL12.
The automated docking simulation exemplified by JG6-CXCL12 interaction was performed to understand the interaction mode between them. The crystal structure of human CXCL12 was utilized as the target structure, whereas the disaccharide of JG6 was used as a docking probe. We found that JG6 docked well to CXCL12 with a low docking energy at -13.08 kcal/mol. JG6 appeared to interact with CXCL12 via multiple polar interactions, including 6 ionic bonds and 7 hydrogen bonds ( Figure 5 ).
These data, taken together, suggested that JG6 impaired the CXCL12/CXCR4 axis likely via a direct interaction with the chemokine CXCL12, which resulted in impaired intracellular signal transduction downstream of CXCL12 stimulation.
Discussion
The CXCL12/CXCR4 axis plays a critical role in cancer progression, including cell proliferation, survival, angiogenesis and particularly chemotactic metastasis. As a result, the CXCL12/CXCR4 axis has become a widely studied anti-cancer drug target. In this study, we have shown that JG6, a novel marine-derived oligosaccharide, interferes with the CXCL12/ CXCR4 signaling axis and its associated biological functions in cancer cells. JG6 not only significantly reversed CXCL12-induced proliferation of cancer cells but also dramatically diminished CXCL12-mediated cell migration in vitro.
CXCL12 binds to GAGs, such as heparin sulfate (HS). CXCL12 binds to the S-domains of HS with high affinity predominantly through 2-O-and N-sulfate groups [16] . HS chains are linear repeating polymers composed of β-D-glucuronate and α-D-N-acetylglucosamine [17] with a relatively uniform pattern of alternating sulfated and unmodified regions along the HS chain [18] . Previous studies of HS structure have identified a CXCL12-binding domain [8, 19] . Moreover, a series of sulfated GAG mimetics targeting CXCL12 exhibited anticancer activity [11] . Based on the structural similarity between JG6 and GAGs, we hypothesized that JG6 was likely to bind to CXCL12. Using the SPR assay, we showed that JG6, like www.chinaphar.com Wen WW et al Acta Pharmacologica Sinica npg HS, directly binds to CXCL12 in a multivalent binding mode, which was consistent with the molecular docking model of the interaction. The calculated energy showed that JG6 can effectively bind to CXCL12 with a relatively low energy (-13.28 kcal/mol). Together, these results suggest that JG6 may directly interact with CXCL12, thereby blocking the CXCL12/ CXCR4 axis and the subsequent biological functions such as tumor growth and migration.
In summary, our study shows that the structural features of JG6 enable it to interact with CXCL12 and provides an alternative for targeting the CXCL12/CXCR4 axis. The impact of JG6 on the CXCL12/CXCR4 axis may account for the anticancer activity of JG6. 
